quinoxalines has been researched along with Non-alcoholic Fatty Liver Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aishima, S; Anzai, K; Eguchi, Y; Imajo, K; Itoh, Y; Kage, M; Moriguchi, M; Nakajima, A; Oeda, S; Ogawa, Y; Seko, Y; Takahashi, H; Yoneda, M | 1 |
| Cho, SS; Ki, SH; Kim, KM | 1 |
| Kato, H; Morishita, S; Murakoshi, M; Nishino, H; Ono, T; Saito, K; Sugiyama, K; Tomita, K | 1 |
1 review(s) available for quinoxalines and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Emerging roles of ferroptosis in liver pathophysiology.
Topics: Animals; Antineoplastic Agents; Caffeic Acids; Carcinoma, Hepatocellular; Cycloheximide; Cyclohexylamines; Deferoxamine; Disease Models, Animal; Disease Progression; Fatty Acids, Unsaturated; Ferroptosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Lipid Peroxidation; Liver; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Phenylenediamines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Spiro Compounds | 2020 |
2 other study(ies) available for quinoxalines and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Area Under Curve; Aspartate Aminotransferases; Biopsy; Body Mass Index; Elasticity Imaging Techniques; Female; gamma-Glutamyltransferase; Humans; Imidazoles; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Quinoxalines; ROC Curve; Young Adult | 2020 |
Lactoferrin attenuates fatty acid-induced lipotoxicity via Akt signaling in hepatocarcinoma cells.
Topics: Animals; Anthracenes; Apoptosis; Benzimidazoles; Cattle; Fatty Acids, Nonesterified; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Lactoferrin; Lipid Metabolism; Lipotropic Agents; Liver; MAP Kinase Signaling System; Non-alcoholic Fatty Liver Disease; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinoxalines | 2015 |